查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
支氣管鏡市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)
市場調查報告書
商品編碼
1190157

支氣管鏡市場 - COVID-19 的增長、趨勢、影響和預測 (2023-2028)

Bronchoscope Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 115 Pages | 商品交期: 2-3個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

在預測期內，支氣管鏡市場預計將以 7.2% 的複合年增長率增長。

支氣管鏡在 COVID-19 及相關疾病檢測中的應用對市場增長產生了積極影響。 COVID-19引起的肺炎很可能導致低氧血症和呼吸衰竭，需要支氣管鏡檢查。 例如，根據歐洲呼吸學會 2021 年 4 月發表的一篇論文，通過支氣管鏡清除粘液栓和支氣管內凝塊並解決 COVID-19 重症患者的肺不張導致機械通氣可以得到改善。 此外，根據 Ambu A/S 2021/22 年年度報告，由於 2020/21 年比較高的市場庫存和競爭加劇（尤其是在美國市場）帶來的高市場庫存，支氣管鏡行業正面臨挑戰。說他做到了。 全球支氣管鏡業務銷售額增長了 70%，反映了從可重複使用的內窺鏡向一次性設備的轉變，儘管與 COVID-19 之前相比有所下降。 因此，總體而言，可以說自 COVID-19 大流行以來對支氣管鏡市場產生了重大影響。

呼吸系統疾病和肺癌負擔的增加、醫院對支氣管鏡檢查設施投資的增加以及技術進步預計將推動支氣管鏡檢查市場。 例如，根據美國癌症協會 2022，肺癌（包括小細胞和非小細胞）是美國男性和女性中第二大最常見的癌症。 此外，根據 2022 年國際呼吸學會論壇報告，估計約有 2 億人患有慢性阻塞性肺病，2.62 億人患有哮喘。 此類呼吸系統疾病的高患病率和癌症患者數量的增加預計將增加對用於診斷該疾病的支氣管鏡的需求，最終推動市場。

此外，市場參與者頻繁推出新產品並在各自細分市場採取不同的增長策略，這有望推動市場增長。 例如，2021 年 4 月，奧林巴斯宣布推出公司首款一次性支氣管鏡 H-SteriScopes，從而擴大其呼吸產品組合。 奧林巴斯全資子公司維蘭醫療與湖南華信醫療強強聯手，推出H-SteriScope系列產品。 此外，2021 年 5 月，PENTAX Medical Europe 的新型一次性支氣管鏡 PENTAX Medical ONE Pulmo 獲得了 CE 標誌。 這種創新產品可在不影響肺部護理的情況下提供高質量護理。 PENTAX Medical ONE Pulmo 是一款一次性支氣管鏡，具有出色的吸力和高清圖像質量。 因此，上述因素正在影響氣管鏡市場的增長。 然而，預計與支氣管鏡檢查程序相關的高額管理費用將阻礙預測期內的市場增長。

主要市場趨勢

一次性支氣管鏡有望在預測期內快速增長。

與可重複使用的支氣管鏡相比，ICU 和圍手術期麻醉師使用的一次性支氣管鏡具有可接受的性能水平，並且由於無菌而降低感染風險具有明顯優勢。 一次性使用的支氣管鏡消除了與可重複使用的支氣管鏡的交叉污染，並且在某些臨床環境中更具成本效益。 它們有助於檢測腫瘤、慢性阻塞性肺病、肺癌和許多其他疾病。 例如，國家醫學圖書館於 2022 年 1 月發表的一項研究發現，在支氣管鏡檢查和重症監護病房的某些情況下，使用一次性支氣管鏡優於可重複使用的支氣管鏡可提高便攜性，它受益於即時可用性和理論上較低的臨床相關感染風險。 此外，根據國家醫學圖書館 2022 年 1 月發表的一篇論文，一次性支氣管鏡被認為是可重複使用的，僅考慮在典型的 ICU 環境中支氣管鏡交叉污染和隨後感染的可能性。據說成本更高-比支氣管鏡檢查有效。 因此，一次性支氣管鏡相對於可重複使用支氣管鏡的上述優勢有望推動該領域的增長。

此外，主要市場參與者的技術產品進步預計將推動該細分市場的增長。 例如，2021 年 8 月，波士頓科學公司的 EXALT B 型一次性支氣管鏡獲得了美國 FDA 510(k) 許可，該鏡設計用於重症監護病房 (ICU) 和手術室的床邊手術。我得到了 預計這些進步將在預測期內推動市場增長。 因此，所有上述因素預計將在預測期內推動分部增長。

預計在預測期內北美將主導支氣管鏡市場

由於支氣管鏡檢查程序的數量不斷增加以及慢性阻塞性肺病、肺炎和肺癌等呼吸系統疾病的高發率，預計北美將在支氣管鏡檢查市場佔據很大的市場份額。 例如，根據 NCBI 2021 年 6 月的一份報告，美國每年大約進行 500,000 次支氣管鏡手術。 此外，根據 ACS 的數據，預計 2022 年美國將診斷出的肺癌病例估計約為 236,740 例新病例。 同樣，根據加拿大癌症協會的數據，預計到 2022 年加拿大將新增約 30,000 例肺癌病例。 這導致了研究市場的增長，因為北美對支氣管鏡的需求很高，表明該地區肺癌的負擔。 因此，有望推動支氣管鏡的市場增長。

此外，新產品的推出也將有利於整個細分市場在預測期內的增長。 例如，2021 年 7 月，Verathon 將推出 GlideScope BFlex 一次性支氣管鏡，它提供一次性支氣管鏡的可訪問性，同時提供通常與可重複使用的支氣管鏡相關的圖像和控制。 預計這種區域進步將促進市場的增長。 因此，由於上述因素，預計北美地區的市場將在預測期內增長。

競爭格局

由於多家公司在全球和區域運營，因此支氣管鏡市場本質上是分散的。 競爭格局包括擁有市場份額的知名國際企業，如 Teleflex Inc.、Karl Storz GmbH、Olympus Corporation、Lymol Medical、Fujifilm Holdings Corporation、Broncus Medical Inc、Novatech SA、Boston Scientific Corporation、Pentax Medical、Ambu A/S . 和國內公司的分析。

其他好處

  • Excel 格式的市場預測 (ME) 表
  • 3 個月的分析師支持

內容

第一章介紹

  • 研究假設和市場定義
  • 調查範圍

第二章研究方法論

第 3 章執行摘要

第四章市場動態

  • 市場概覽
  • 市場驅動因素
    • 呼吸系統疾病和肺癌的負擔不斷增加
    • 增加醫院對支氣管鏡檢查設施的投資
    • 技術進步
  • 市場製約因素
    • 支氣管鏡檢查費用高昂
  • 波特的五力分析
    • 新進入者的威脅
    • 買方/消費者議價能力
    • 供應商的議價能力
    • 替代品的威脅
    • 競爭公司之間的敵對關係

第 5 章市場細分（基於價值的市場規模 - 百萬美元）

  • 按產品類型
    • 剛性
    • 靈活
    • 配飾
  • 通過使用
    • 一次性型
    • 可重複使用類型
  • 按地區
    • 北美
      • 美國
      • 加拿大
      • 墨西哥
    • 歐洲
      • 德國
      • 英國
      • 法國
      • 意大利
      • 西班牙
      • 其他歐洲地區
    • 亞太地區
      • 中國
      • 日本
      • 印度
      • 澳大利亞
      • 韓國
      • 其他亞太地區
    • 中東和非洲
      • 海灣合作委員會
      • 南非
      • 其他中東地區
    • 南美洲地區
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章競爭格局

  • 公司簡介
    • Ambu A/S
    • Boston Scientific Corporation
    • Broncus Medical Inc.
    • Fujifilm Holdings Corporation
    • Karl Storz GmbH
    • Lymol Medical
    • Novatech SA
    • Olympus Corporation
    • Pentax Medical
    • Teleflex Inc.

第7章 市場機會今後動向

簡介目錄
Product Code: 68148

The bronchoscope market is expected to register a CAGR of 7.2% over the forecast period.

The application of a bronchoscope for the examination of COVID-19 and associated diseases has positively impacted the growth of the market. Pneumonia caused by COVID-19 was likely to cause hypoxemia and respiratory failure, necessitating a bronchoscope for the examination. For instance, as per an article published by the European Respiratory Society, in April 2021, in critically ill patients with COVID-19, bronchoscopy allows the removal of mucus plugs and intrabronchial clots, and the resolution of atelectasis, thereby improving mechanical ventilation. Furthermore, according to Ambu A/S annual report, 2021/22, the bronchoscopy industry experienced challenges as a result of high market inventories and greater competition, particularly in the American market, brought on by the high comparative from 2020/21. Despite the year's lower performance compared to pre- COVID-19, bronchoscopy business revenue worldwide increased by 70%, indicating the switch from reusable endoscopy to single-use equipment. Therefore, overall, the COVID-19 pandemic had a profound impact on the bronchoscope market since during the pandemic.

The growing burden of respiratory diseases and lung cancer, growing hospital investment in bronchoscopy facilities, and technological advancements are expected to drive the bronchoscope market. For instance, as per the American Cancer Society 2022, lung cancer (both small cell and non-small cell) is the second most common cancer in both men and women in United States. Furthermore, according to the Forum of International Respiratory Societies report 2022, approximately 200 million people are estimated to have COPD, and 262 million people are affected by Asthma. With such a high prevalence of respiratory disease and a rise in cancer cases, the demand for bronchoscopes is expected to increase for the diagnosis of this disease eventually driving the market.

Moreover, market players are frequently launching new products and adopting various growth strategies in their respective segments, which is likely to drive market growth. For instance, in April 2021, Olympus announced the expansion of its respiratory portfolio with the launch of our first line of single-use bronchoscopes, the H-SteriScopes. Veran Medical Technologies, Inc., a wholly owned Olympus subsidiary, and Hunan Vathin Medical Instrument Co., Ltd. worked together to launch the H-SteriScope range. Additionally, in May 2021, PENTAX Medical Europe, has obtained a CE mark for its new single-use bronchoscope - the PENTAX Medical ONE Pulmo. This innovative product provides high-quality care without compromising pulmonary care. The PENTAX Medical ONE Pulmo is a single-use bronchoscope with superior suction power and HD image quality. Thus, the abovementioned factors are impacting the market growth of over the bronchoscope market. However, the high overhead cost of bronchoscopy procedures is expected to hinder market growth over the forecast period.

Key Market Trends

Single Use Bronchoscope Segment is Expected to Witness High Growth Over the Forecast Period

The single-use flexible bronchoscope is used by anesthetists in an ICU or peri-operative setting where they perform to an acceptable level in comparison to reusable flexible bronchoscopes combined with the distinct advantage of a reduced risk of infection owing to their sterility. Single-use flexible bronchoscopes eliminate cross-contamination from reusable bronchoscopes and are cost-effective in several clinical settings. These are helpful for the detection of diseases like tumors, COPD, cancer of the lungs, and many more. For instance, according to the study published by the National Library of Medicine, in January 2022, in certain circumstances in the bronchoscopy and intensive care units, using a single-use bronchoscope over a reusable bronchoscope confers an advantage due to its portability, immediate availability, and theoretically lower risk of clinically relevant infections. Furthermore, according to an article published by the National Library of Medicine, in January 2022, a single-use flexible bronchoscope is cost-effective when solely looking at cross-contamination and possible subsequent infections with bronchoscopes in a typical ICU setting compared with reusable flexible bronchoscope. Thus, the above benefits of a single-use bronchoscope over the reusable bronchoscope are expected to boost segment growth.

Furthermore, the technological product advancements by significant market players are expected to boost segment growth. For instance, in August 2021, Boston Scientific Corporation received U.S. FDA 510(k) clearance for the EXALT Model B Single-Use Bronchoscope, designed for use in bedside procedures within the intensive care unit (ICU) and operating room. Such advancement is expected to drive the growth of the market over the forecast period. Thus, all aforementioned factors are expected to boost segment growth over the forecast period.

North America is Expected to Dominate the Bronchoscope Market Over the Forecast Period

North America is expected to hold a significant market share in the bronchoscope market due to the increasing number of bronchoscopy procedures and higher prevalence rates of respiratory diseases such as COPD, pneumonia, and lung cancer. For instance, according to the NCBI report of June 2021, around 500 thousand procedures of bronchoscopies are performed in United States every year. Furthermore, as per ACS, the estimated number of lung cancer expected to be diagnosed in United States in 2022 is about 236,740 new cases. Similarly, according to the Canadian Cancer Society, about 30,0000 new cases of lung cancer are estimated to be recorded in Canada in 2022. This indicates the burden of lung cancer in the region, which results in the growth of the market studied as there is a high demand for bronchoscopes in North America. Hence, it is expected to boost the bronchoscope market growth.

Additionally, new product launches will also favor the overall segment growth over the forecast period. For instance, in July 2021, Verathon launched the GlideScope BFlex single-use bronchoscope which provides the accessibility of a single-use bronchoscope while delivering the images and control typically associated with a reusable bronchoscope. Such regional advancement is expected to boost the market growth. Thus, owing to the abovementioned factors, the studied market in the North American region is expected to project growth over the forecast period.

Competitive Landscape

The bronchoscope market is fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international as well as local companies which hold market shares and are well known including Teleflex Inc., Karl Storz GmbH, Olympus Corporation, Lymol Medical, Fujifilm Holdings Corporation, Broncus Medical Inc, Novatech SA, Boston Scientific Corporation, Pentax Medical, and Ambu A/S, among others.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions & Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Burden of Respiratory Diseases and Lung Cancer
    • 4.2.2 Growing Hospital Investment in Bronchoscopy Facility
    • 4.2.3 Technological Advancements
  • 4.3 Market Restraints
    • 4.3.1 High Overhead Cost of Bronchoscopy Procedure
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Rigid
    • 5.1.2 Flexible
    • 5.1.3 Accessories
  • 5.2 By Usage
    • 5.2.1 Single Use Bronchoscope
    • 5.2.2 Reusable Bronchoscope
  • 5.3 Geography
    • 5.3.1 North America
      • 5.3.1.1 United States
      • 5.3.1.2 Canada
      • 5.3.1.3 Mexico
    • 5.3.2 Europe
      • 5.3.2.1 Germany
      • 5.3.2.2 United Kingdom
      • 5.3.2.3 France
      • 5.3.2.4 Italy
      • 5.3.2.5 Spain
      • 5.3.2.6 Rest of Europe
    • 5.3.3 Asia-Pacific
      • 5.3.3.1 China
      • 5.3.3.2 Japan
      • 5.3.3.3 India
      • 5.3.3.4 Australia
      • 5.3.3.5 South Korea
      • 5.3.3.6 Rest of Asia-Pacific
    • 5.3.4 Middle East and Africa
      • 5.3.4.1 GCC
      • 5.3.4.2 South Africa
      • 5.3.4.3 Rest of Middle East and Africa
    • 5.3.5 South America
      • 5.3.5.1 Brazil
      • 5.3.5.2 Argentina
      • 5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Ambu A/S
    • 6.1.2 Boston Scientific Corporation
    • 6.1.3 Broncus Medical Inc.
    • 6.1.4 Fujifilm Holdings Corporation
    • 6.1.5 Karl Storz GmbH
    • 6.1.6 Lymol Medical
    • 6.1.7 Novatech SA
    • 6.1.8 Olympus Corporation
    • 6.1.9 Pentax Medical
    • 6.1.10 Teleflex Inc.

7 MARKET OPPORTUNITIES AND FUTURE TRENDS